Island Pharmaceuticals (ASX:ILA) Net Income From Continuing Operations: A$-9.84 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
30 GF Score
Price A$0.47
! 1 Warning Sign
View Full Analysis

What is Island Pharmaceuticals Net Income From Continuing Operations?

Island Pharmaceuticals ASX:ILA +6.82% 30 Net Income From Continuing Operations is A$-9.84 Mil as of Jun. 2026. GuruFocus rates ASX:ILA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Island Pharmaceuticals's net income from continuing operations for the six months ended in Jun. 2026 was A$-5.03 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was A$-9.84 Mil.

Island Pharmaceuticals Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Island Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Net Income From Continuing Operations Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Net Income From Continuing Operations
Get a 7-Day Free Trial -2.61 -2.83 -2.86 -3.92 -9.84

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.71 -1.53 -2.39 -4.81 -5.03
ASX:ILA
30GF Score
Island Pharmaceuticals Ltd ASX:ILA
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Island Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-9.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of A$-9.84 Mil mean?
Island Pharmaceuticals (ASX:ILA) has a Net Income From Continuing Operations of A$-9.84 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Island Pharmaceuticals and its competitors.
Is Island Pharmaceuticals' Net Income From Continuing Operations too high?
Island Pharmaceuticals' current Net Income From Continuing Operations is A$-9.84 Mil. Overall, Island Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Net Income From Continuing Operations compare to VRTX and REGN?
Island Pharmaceuticals' Net Income From Continuing Operations of A$-9.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current Net Income From Continuing Operations is A$-9.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Net Income From Continuing Operations of A$-9.84 Mil. The current Net Income From Continuing Operations is A$-9.84 Mil. Island Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Net Income From Continuing Operations is A$-9.84 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Other Exchanges 7X0:Germany
Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
30GF Score

Get the complete analysis for ASX:ILA

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.47
Price